Platelets from diabetic pigs exhibit hypersensitivity to thrombin

Comparative Medicine

Volumn 58, Issue 5, 2008, Pages 481-484

  Shukla, Shivendra D ^a   Kansra, Sanjay V ^a,b   Reddy, M A ^a   Shukla, Sundeep M ^a   Klachko, David M ^a   Sturek, Michael ^a,c  

^a University of Missouri   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOXAN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHOTRANSFERASE; THROMBIN;

ALLERGIC REACTION; ALLOXAN DIABETES MELLITUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL DESTRUCTION; CORRELATION ANALYSIS; DIABETES MELLITUS; DRUG INDUCED DISEASE; ENZYME REGULATION; HYPERLIPIDEMIA; HYPERSENSITIVITY REACTION; NONHUMAN; PANCREAS ISLET BETA CELL; PLASMA FACTOR; SENSITIVITY ANALYSIS; SWINE; THROMBOCYTE; THROMBOCYTE AGGREGATION;

ANIMALS; BLOOD PLATELETS; DIABETES MELLITUS, EXPERIMENTAL; DOWN-REGULATION; HYPERLIPIDEMIAS; MITOGEN-ACTIVATED PROTEIN KINASES; PLATELET AGGREGATION; SWINE; THROMBIN; TIME FACTORS;

EID: 56549117429     PISSN: 15320820     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Ahn NG, Weil JE, Chan CP, Krebs EG. 1990. Identification of multiple EGF-stimulated protein serine/threonine kinases from Swiss 3T3 cells. J Biol Chem 265:11487-11494.
2. Carter AJ, Bailey L, Devries J, Hubbard B. 2000. The effects of uncontrolled hyperglycemia on thrombosis and formation of neointima after coronary stent placement in a novel diabetic porcine model of restenosis. Coron Artery Dis 11:473-479.
3. Colwell JA, Nesto RW. 2003. The platelet in diabetes. Diabetes Care 26:2181-2188.
4. Dixon JL, Stoops JD, Parker JL, Laughlin MH, Weisman GA, Sturek M. 1999. Dyslipidemia and vascular dysfunction in diabetic pig fed an atherogenic diet. Arterioscler Thromb Vasc Biol 19:2981-2992.
5. Eldor A, Merin S, Bar-On H. 1978. The effect of streptozotocin diabetes on platelet function in rats. Thromb Res 13:703-714.
6. Goodman SL. 1999. Sheep, pig, and human platelet-material interactions with model cardiovascular materials. J Biomed Mater Res 45:240-250.
7. Henderson KK, Mokelke EA, Turk JR, Rector RS, Laughlin MH, Sturek M. 2003. Maintaining vascular access port patency and asepsis in Yucatan miniature swine. Contemp Top Lab Anim Sci 42:28-32.
8. Ho H, Shukla SD, Klachko DM. 1998. In vitro effect of elevated glucose on human platelet aggregation. EndoTrends 5:5-7.
9. Holinstat M, Voss B, Bilodeau ML, McLaughlin JN, Cleator J, Hamm HE. 2006. PAR4, but not PAR1, signals human nplatelet aggregation via calcium mobilization and synergistic P2Y12 receptor activation. J Biol Chem 281:26665-26674.
10. Hsueh W, Abel ED, Breslow JL, Maeda N, Davis RC, Fisher EA, Dansky H, McClain DA, McIndoe R, Wassef MK, Rabadán-Diehl C, Goldberg IJ. 2007. Recipes for creating animal models of diabetic cardiovascular disease. Circ Res 100:1415-1427.
11. Kansra SV, Reddy MA, Weng Y, Shukla SD. 1999. Activation of human platelet MAP Kinase by genistein. Pharmacol Res 39:21-31.
12. Kansra SV, Shukla SD. 2000. Reverse relationship between MAP kinase and human platelet aggregation. Clin Exp Hypertens 22:145-154.
13. Keating FK, Sobel BE, Schneider DJ. 2003. Effects of increased concentrations of glucose on platelet reactivity in healthy subjects and in patients with and without diabetes mellitus. Am J Cardiol 92:1362-1365.
14. Leger AJ, Covic L, Kuliopulos A. 2006. Protease-activated receptors in cardiovascular diseases. Circulation 114:1070-1077.
15. 2+ signaling, tyrosine phosphorylation, and coronary artery disease in diabetic dyslipidemic swine are prevented by atorvastatin. J Pharmacol Exp Ther 306:132-140.
16. Otis CR, Wamhoff BR, Sturek M. 2003. Hyperglycemia-induced insulin resistance in diabetic dyslipidemic Yucatan swine. Comp Med 53:53-64.
17. Paul W, Queen LR, Page CP, Ferro A. 2007. Increased platelet aggregation in vivo in the Zucker diabetic fatty rat: differences from the streptozotocin diabetic rat. Br J Pharmacol 150:105-111.
18. Phillips RW, Panepinto LM. 1986. Swine as a model for human diabetes. In: Tumbelson ME, editor. Swine in biomedical research, vol 1. New York: Plenum Press. p 549-560.
19. 3H] serotonin secretion. Arch Biochem Biophys 232:458-466.
20. Shukla SD, Paul A, Klachko D. 1992. Hypersensitivity of diabetic human platelets to platelet activating factor. Thromb Res 66:239-246.
21. Sturek M, Alloosh M, Wenzel J, Byrd JP, Edwards JM, Lloyd PG, Tune JD, March KL, Miller MA, Mokelke EA, Brisbin IL Jr. 2007. Ossabaw Island miniature swine: cardiometabolic syndrome assessment. In: Swindle MM, editor. Swine in the laboratory: surgery, anesthesia, imaging, and experimental techniques, 2nd ed. Boca Raton (FL): CRC Press. p 397-402.
22. Sudic D, Razmara M, Forslund M, Ji Q, Hjemdahl P, Li N. 2006. High glucose levels enhance platelet activation: involvement of multiple mechanisms. Br J Haematol 133:315-322.
23. Vericel E, Januel C, Carreras M, Moulin P, Lagarde M. 2004. Diabetic patients without vascular complications display enhanced basal platelet activation and decreased antioxidant status. Diabetes 53:1046-1051.
24. Vinik AI, Erbas T, Park TS, Nolan R, Pittenger GL. 2001. Platelet dysfunction in type 2 diabetes. Diabetes Care 24:1476-1485.
25. Winocour PD. 1992. Platelet abnormalities in diabetes mellitus. Diabetes 41 Suppl 2:26-31.
26. 2+ dysregulation in coronary smooth muscle from diabetic dyslipidemic Yucatan swine. J Appl Physiol 101:752-762.
27. Zahn R, Hamm CW, Schneider S, Zeymer U, Richardt G, Kelm M, Levenson B, Bonzel T, Tebbe U, Sabin G. 2006. Predictors of death or myocardial infarction during follow-up after coronary stenting with the sirolimus-eluting stent. Results from the prospective multicenter German Cypher Stent Registry. Am Heart J 152:1146-1152.